Scenic Biotech is applying a novel approach to target discovery by harnessing genetic modifiers. Powered by our proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. These insights enable us to rapidly identify and validate novel drug targets and then focus on the development of medicines with the greatest potential to impact the lives of patients.
Scenic Biotech is a spinout of the Netherlands Cancer Institute and Oxford University, and is financially backed by BioGeneration Ventures, Inkef Capital, and Oxford Sciences Innovation. Scenic Biotech has initiated a pipeline of preclinical discovery programs and was founded in 2017.